MANNKIND CORP SEC Filings

MannKind Corporation (MNKD) has filed a prospectus supplement registering for resale up to 12,853,470 shares of common stock by existing selling stockholders. This total includes 10,440,838 issued shares and 2,412,632 shares issuable upon exercise of outstanding pre-funded warrants from a July 24, 2026 private placement.

The company sold the private placement securities at $3.89 per common share and $3.88 per pre-funded warrant, with each pre-funded warrant carrying a $0.01 exercise price and no expiration until exercised, subject to a beneficial ownership limitation not to exceed 19.99%. MannKind will not receive any proceeds from the resale of these shares, though it is paying the registration and related offering expenses.

The selling stockholders may dispose of shares through various methods, including market and negotiated transactions, and may use underwriters, broker-dealers or agents. MannKind’s common stock trades on the Nasdaq Global Market under the symbol MNKD; the last reported sale price was $4.26 per share on August 20, 2026. Shares outstanding were 321,544,484 as of August 14, 2026, a baseline figure distinct from the shares registered for resale.

Rubric Capital Management LP and David Rosen reported a passive ownership position in MannKind Corporation common stock. They beneficially own 18,000,000 shares, representing 5.83% of the outstanding common stock, with shared voting and dispositive power over all reported shares and no sole power. The percentage is based on 308,950,166 shares outstanding as of April 24, 2026, as stated in MannKind’s Form 10-Q. Rubric Capital Master Fund LP has the right to receive dividends and sale proceeds from more than 5% of the common stock.

MannKind Corp director Steven B. Binder reported selling 39,051 shares of common stock on 2026-08-07 in an open-market transaction under a pre-established Rule 10b5-1 trading plan. The weighted average sale price was $4.06 per share, and Binder now directly holds 785,867 shares of MannKind common stock.

MannKind Corporation insider Steven Binder filed to sell MannKind common stock under Rule 144. The planned transaction involves up to 39,051 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.

The filing also lists recent 10b5-1 plan sales of MannKind common stock by Steven Binder, including 52,485 shares on 07/17/2026 for $212,837.17 and 16,940 shares on 05/12/2026 for $55,766.48.

MannKind Corporation reported net revenue of $109.4 million for the quarter ended June 30, 2026 and $199.5 million for the first six months of 2026, compared with $76.5 million and $154.9 million in the prior-year periods. Product sales, including Afrezza, V-Go and newly added Furoscix, totaled $127.5 million for the six months, while royalties from Tyvaso DPI contributed $65.1 million.

The company recorded a quarterly net loss of $19.0 million and a six‑month net loss of $35.7 million, versus net income of $0.7 million and $13.8 million a year earlier. Higher selling, general and administrative expense of $112.4 million, research and development of $35.2 million, amortization of acquired intangibles of $8.7 million and total interest expense of $27.3 million weighed on results. Net cash used in operating activities was $23.7 million for the six months.

As of June 30, 2026, cash, cash equivalents and restricted cash were $53.7 million, with additional short‑term investments of $58.2 million. Total liabilities were $799.5 million, including a $319.1 million term loan and liabilities related to the sale of future royalties and CVR contingent consideration, resulting in stockholders’ deficit of $67.2 million. United Therapeutics accounted for about 61% of consolidated revenues for both the three and six‑month periods. Following the 2025 scPharmaceuticals merger, the company recorded developed technology and IPR&D intangibles and goodwill, and achievement of CVR Milestone 1 in July 2026 will trigger an aggregate payout of approximately $44.8 million.

MannKind Corporation reported Q2 2026 total revenues of $109,374 (thousands), a 43% increase from Q2 2025, driven by the addition of Furoscix, higher collaborations and services revenue, and royalties tied to Tyvaso DPI. Commercial product sales were $41,982 (thousands), including Furoscix net sales of $22,191 (thousands) and Afrezza net sales of $17,021 (thousands). For the first six months of 2026, total revenues reached $199,544 (thousands), up 29% year over year.

Higher cost of goods, research and development, and selling, general and administrative expenses, largely associated with Furoscix and pipeline advancement, led to a Q2 2026 net loss of $19,032 (thousands), or $0.06 per basic share, compared with net income of $668 (thousands) a year earlier. Non-GAAP adjusted net loss was $2,660 (thousands) versus non-GAAP income of $13,901 (thousands). Cash, cash equivalents and investments totaled $111 million as of June 30, 2026, and a $50 million private placement closed on July 24, 2026 to fund a $45 million contingent value right payment following FDA approval of the Furoscix ReadyFlow autoinjector. During 2026, MannKind also received FDA approval for a pediatric indication for Afrezza and reported positive Phase 1b data for its nintedanib DPI program while preparing an IND for ralinepag DPI.

Vanguard Capital Management LLC and certain affiliates report passive ownership of MannKind Corp common stock on Schedule 13G. They beneficially own 15,450,421 shares, representing 5% of the outstanding common stock as of June 30, 2026.

Vanguard has sole voting power over 2,281,029 shares and sole dispositive power over all 15,450,421 shares, with no shared voting or dispositive power. The position is held across Vanguard funds and managed accounts, and no other single underlying investor is reported to hold more than 5% of the class through these holdings.

MannKind Corporation completed a $50.0 million private placement with institutional accredited investors, selling 10,440,838 shares of common stock at $3.89 per share and pre-funded warrants for 2,412,632 underlying shares at $3.88 per warrant share. The pre-funded warrants have a $0.01 exercise price, are exercisable on a cashless basis, do not expire until fully exercised, and include a beneficial ownership limitation not to exceed 19.99%.

The company plans to use net proceeds for general corporate purposes, including funding a $45.0 million contingent value rights payment obligation triggered by the U.S. Food and Drug Administration’s approval of Furoscix ReadyFlow (furosemide injection). The securities were issued under the Section 4(a)(2) exemption, with resale registration rights for the shares and warrant shares to be filed within 30 days of closing. Separately, the FDA approved Furoscix ReadyFlow to treat edema in adults with heart failure or chronic kidney disease.

MANNKIND CORP Chief Financial Officer Christopher B. Prentiss reported two tax-withholding dispositions of common stock on July 15, 2026, totaling 22,247 shares at $4.09 per share. The shares were delivered or withheld to satisfy exercise price or tax liabilities upon vesting of previously reported restricted stock units under Rule 16b-3. His reported direct holdings include 1,991 shares acquired through the Employee Stock Purchase Plan on June 30, 2026.